ES2368864T3 - Anticuerpos monoclonales anti-met, sus fragmentos y vectores para el tratamiento de tumores y productos correspondientes. - Google Patents

Anticuerpos monoclonales anti-met, sus fragmentos y vectores para el tratamiento de tumores y productos correspondientes. Download PDF

Info

Publication number
ES2368864T3
ES2368864T3 ES07704350T ES07704350T ES2368864T3 ES 2368864 T3 ES2368864 T3 ES 2368864T3 ES 07704350 T ES07704350 T ES 07704350T ES 07704350 T ES07704350 T ES 07704350T ES 2368864 T3 ES2368864 T3 ES 2368864T3
Authority
ES
Spain
Prior art keywords
cdr
seq
antimet
antibody
hgfr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07704350T
Other languages
English (en)
Spanish (es)
Inventor
Paolo Maria Comoglio
Elisa Vigna
Silvia Giordano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
METHERESIS TRANSLATIONAL RESEARCH SA
Metheresis Translational Res SA
Original Assignee
METHERESIS TRANSLATIONAL RESEARCH SA
Metheresis Translational Res SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by METHERESIS TRANSLATIONAL RESEARCH SA, Metheresis Translational Res SA filed Critical METHERESIS TRANSLATIONAL RESEARCH SA
Application granted granted Critical
Publication of ES2368864T3 publication Critical patent/ES2368864T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES07704350T 2006-02-06 2007-02-05 Anticuerpos monoclonales anti-met, sus fragmentos y vectores para el tratamiento de tumores y productos correspondientes. Active ES2368864T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06101345 2006-02-06
EP06101345 2006-02-06

Publications (1)

Publication Number Publication Date
ES2368864T3 true ES2368864T3 (es) 2011-11-23

Family

ID=36616994

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07704350T Active ES2368864T3 (es) 2006-02-06 2007-02-05 Anticuerpos monoclonales anti-met, sus fragmentos y vectores para el tratamiento de tumores y productos correspondientes.

Country Status (21)

Country Link
US (2) US8388958B2 (enExample)
EP (2) EP1981981B1 (enExample)
JP (1) JP5306828B2 (enExample)
KR (1) KR101429297B1 (enExample)
CN (1) CN101379192B (enExample)
AT (1) ATE514715T1 (enExample)
AU (1) AU2007213804B2 (enExample)
BR (1) BRPI0707480A8 (enExample)
CA (1) CA2638889C (enExample)
CY (1) CY1111884T1 (enExample)
DK (1) DK1981981T3 (enExample)
EA (1) EA015580B1 (enExample)
ES (1) ES2368864T3 (enExample)
IL (1) IL192879A (enExample)
MX (1) MX2008009833A (enExample)
PL (1) PL1981981T3 (enExample)
PT (1) PT1981981E (enExample)
SG (2) SG169383A1 (enExample)
SI (1) SI1981981T1 (enExample)
WO (1) WO2007090807A1 (enExample)
ZA (1) ZA200806559B (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2014681A1 (en) 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
IL198545A0 (en) * 2008-05-14 2011-07-31 Metheresis Translational Res Sa High affinity binding site of hgfr and methods for identification of antagonists thereof
EP2127683A1 (en) * 2008-05-29 2009-12-02 Metheresis Translational Research SA Anti-Met monoclonal antibody, fragments and derivatives thereof for use in tumor imaging, corresponding compositions and kits
PA8849001A1 (es) 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
EP2287197A1 (en) * 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer
KR101671378B1 (ko) * 2009-10-30 2016-11-01 삼성전자 주식회사 ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그의 용도
KR101748707B1 (ko) * 2009-11-27 2017-06-20 삼성전자주식회사 ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그를 이용한 암 진단용 키트
WO2011110642A2 (en) 2010-03-10 2011-09-15 Genmab A/S Monoclonal antibodies against c-met
US9175084B2 (en) 2010-04-02 2015-11-03 Fujirebio Inc. Diagnostic marker for effect of anticancer agent
AU2011261161A1 (en) * 2010-06-01 2013-01-10 Ludwig Institute For Cancer Research Limited Antibodies directed to the unprocessed receptor tyrosine kinase c-Met
WO2012030842A2 (en) * 2010-09-03 2012-03-08 Academia Sinica Anti-c-met antibody and methods of use thereof
BR122014027420A2 (pt) 2010-11-03 2019-08-20 Argenx Bvba Anticorpos anti c-met
SI2500036T1 (sl) * 2011-03-18 2014-09-30 Metheresis Translational Research Sa Met inhibitorji za izboljĺ anje uäśinkovitosti obsevanja
US9201074B2 (en) 2011-09-20 2015-12-01 Eli Lilly And Company Anti-c-Met antibodies
WO2013064700A2 (en) 2011-11-03 2013-05-10 Argen-X B.V. Chimeric polypeptides and methods of use
MX2014005885A (es) 2011-11-21 2014-09-04 Genentech Inc Purificacion de anticuerpos anti-c-met.
WO2013079973A1 (en) * 2011-12-02 2013-06-06 Di Cara Danielle Marie Antibodies against hgf - receptor and uses
KR101910601B1 (ko) 2011-12-22 2018-10-23 삼성전자주식회사 면역원성이 제거된 항 ｃ-Ｍｅｔ 인간화 항체 및 그의 용도
CN103382223B (zh) * 2012-04-01 2015-06-10 上海益杰生物技术有限公司 针对表皮生长因子受体隐蔽表位和t细胞抗原的多功能抗体多肽
JP6429771B2 (ja) * 2012-06-21 2018-11-28 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ｃ−Ｍｅｔに結合する抗原結合タンパク質
ITTO20130012A1 (it) 2013-01-09 2014-07-10 Metheresis Translational Res S A Nuovi frammenti anticorpali, relative composizioni ed usi
ES2748295T3 (es) 2014-09-16 2020-03-16 Symphogen As Anticuerpos anti-MET y composiciones
WO2016149116A1 (en) * 2015-03-13 2016-09-22 University Of Maryland, Baltimore Antibodies targeting s100b and methods of use
WO2016149265A1 (en) * 2015-03-16 2016-09-22 Kolltan Pharmaceuticals, Inc. Anti-met antibodies and methods of use thereof
IT201800000534A1 (it) * 2018-01-03 2019-07-03 Procedimenti per la promozione della crescita cellulare degli isolotti pancreatici.
GB201611123D0 (en) * 2016-06-27 2016-08-10 Euremab Srl Anti met antibodiesand uses thereof
MX420249B (es) 2016-09-29 2025-02-10 Mitsubishi Tanabe Pharma Corp Agentes de unión monoclonales de cmet, conjugados de fármaco de los mismos y usos de los mismos.
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
CN106872695B (zh) * 2017-01-20 2019-06-11 中山大学 一种h7亚型禽流感病毒血凝素抗体间接elisa检测试剂盒
IT201800000535A1 (it) 2018-01-03 2019-07-03 Procedimenti per la cura del cancro.
IT201800003875A1 (it) 2018-03-22 2019-09-22 Metis Prec Medicine Sb S R L Nuova combinazione di agenti terapeutici per il trattamento di un tumore e/o metastasi
US12060427B2 (en) * 2018-03-28 2024-08-13 Mitsubishi Tanabe Pharma Corporat Drug conjugates of cMET monoclonal binding agents, and uses thereof
IT201800009282A1 (it) 2018-10-09 2020-04-09 Metis Prec Medicine Sb Srl Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi
JP7750828B2 (ja) 2019-09-16 2025-10-07 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 免疫ｐｅｔ撮像のための放射標識されたｍｅｔ結合タンパク質
TW202448953A (zh) 2023-06-01 2024-12-16 法商皮爾法伯製藥公司 用於腫瘤及轉移之治療的基於沉默抗體的抗met建構物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US6814962B1 (en) 1994-06-02 2004-11-09 Aventis Pharma S.A. Recombinant viruses and their use for treatment of atherosclerosis and other forms of coronary artery disease and method, reagent, and kit for evaluating susceptibility to same
US6214344B1 (en) * 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
HN2004000285A (es) * 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET

Also Published As

Publication number Publication date
CN101379192B (zh) 2013-07-31
IL192879A0 (en) 2009-02-11
IL192879A (en) 2014-02-27
BRPI0707480A8 (pt) 2022-11-08
CA2638889A1 (en) 2007-08-16
KR20090013745A (ko) 2009-02-05
EP1981981A1 (en) 2008-10-22
PL1981981T3 (pl) 2011-11-30
AU2007213804A1 (en) 2007-08-16
US8388958B2 (en) 2013-03-05
KR101429297B1 (ko) 2014-08-12
US8729043B2 (en) 2014-05-20
WO2007090807A1 (en) 2007-08-16
US20120134996A1 (en) 2012-05-31
CY1111884T1 (el) 2015-11-04
AU2007213804B2 (en) 2012-12-13
MX2008009833A (es) 2008-10-23
SG169383A1 (en) 2011-03-30
US20090285807A1 (en) 2009-11-19
SG169382A1 (en) 2011-03-30
EP2192188A1 (en) 2010-06-02
JP5306828B2 (ja) 2013-10-02
PT1981981E (pt) 2011-10-04
ZA200806559B (en) 2012-12-27
JP2009526010A (ja) 2009-07-16
CN101379192A (zh) 2009-03-04
ATE514715T1 (de) 2011-07-15
CA2638889C (en) 2015-06-02
AU2007213804A8 (en) 2008-08-28
BRPI0707480A2 (pt) 2011-05-03
DK1981981T3 (da) 2011-09-26
EA200870234A1 (ru) 2009-02-27
SI1981981T1 (sl) 2012-01-31
EA015580B1 (ru) 2011-10-31
EP1981981B1 (en) 2011-06-29

Similar Documents

Publication Publication Date Title
US8729043B2 (en) Anti-Met monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products
ES2929614T3 (es) Anticuerpos anti-MUC16 y usos de los mismos
Zatovicova et al. Carbonic anhydrase IX as an anticancer therapy target: preclinical evaluation of internalizing monoclonal antibody directed to catalytic domain
US7531304B2 (en) Method for screening FGFR-4 agonists
US20110212091A1 (en) Materials and methods for inhibiting cancer cell invasion
JP2019503709A (ja) ヒト化抗ｃｄ７３抗体
AU2003205716A1 (en) FGFR agonists
US20090123462A1 (en) Fgfr agonists
KR20140075768A (ko) 다발성-골수종 관련 질환 치료에 사용되는 항-icam-1 항체
Kiewlich et al. Anti-EphA2 antibodies decrease EphA2 protein levels in murine CT26 colorectal and human MDA-231 breast tumors but do not inhibit tumor growth
EP2507265B1 (en) Antibody specific for heparanase splice variant T5 and its use.
US9724385B2 (en) STIP1 polypeptides and uses thereof
BR112020018981A2 (pt) Combinação de anticorpo anti-hgfr e hegfr para o tratamento de um tumor e/ou metástase
ES2865303T3 (es) Ligante de adrenomedulina para su uso en la terapia del cáncer
BR112017019978B1 (pt) Anticorpo ou um fragmento de ligação com antígeno, conjugado, receptor de antígeno, polinucleotídeo, vetor, célula microbiana transgênica ex vivo, método para produzir uma célula transgênica ex vivo, método para produzir um anticorpo, composição farmacêutica e uso do anticorpo